Amarin Corp Plc (AMRN)

[Whalatane]

So AMRN sees no benefit in even doing a fairly short ...say 3 yr revascularisation trial like the following ..especially in light of the EU patent extension.

Drug-Coated Balloon (DCB) Angioplasty vs. Bare-Metal Stent (BMS) Implantation: A 6-month trial evaluating the clinical outcomes and restenosis rates between DCB angioplasty and BMS implantation in patients with de novo coronary lesions.
Fractional Flow Reserve (FFR)-Guided PCI vs. Angiography-Guided PCI: A 3-month trial assessing the impact of FFR-guided PCI compared to angiography-guided PCI on long-term outcomes such as major adverse cardiac events (MACE) and target vessel revascularization (TVR).
Bioresorbable Vascular Scaffold (BVS) vs. Drug-Eluting Stent (DES): A 1-year trial comparing the safety and efficacy of BVS with DES in patients undergoing percutaneous coronary intervention for stable angina or acute coronary syndrome.

Based on the graphs Laurent / Capt have posted , there should be very clear separation in event lines by 3 yrs , in revasc rates following a PCI between SOC and SOC plus Vascepa . There probably a lot of RWE data already on this waiting to be analyzed .

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050276

Look at the graphs at 3 yrs
Re your view

Not to mention, there is always the risk that something goes wrong with the trial.

Poor excuse

But no ..let's spend $50m on a share buyback ....and oh by the way ...issue a lot of options for insiders ...a third of which will vest next April

Looking forward to the Great Plan reveal on Wed ( the ER )

Kiwi